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Since 1987, no new structural class of antibiotic has been introduced into human 
medicine. Aside from the absence of a new structural class of antibiotics, there has been a 
startlingly low number of new antibiotics approved since 1987. With the lack of new antibiotics, 
finding current antibiotics that are effective is becoming an alarming challenge due to the 
worldwide emergence of antibiotic resistance. Antibiotic-resistant bacteria presents a major 
threat to public health because they reduce the effectiveness of antibiotic treatment leading to 
increased morbidity, mortality, and healthcare expenditure.1 The antibiotics most affected are 
often older, inexpensive antibiotics that are widely used throughout the world. As a result, 
developing countries face a higher burden as cost constraints prevent the patients in developing 
countries from getting access to the newer, more expensive antibiotics which act as broad 
spectrum or second-line therapies for infectious diseases.2 
Without treatment for common infections, like uropathogenic Escherichia coli (UPEC), 
resistant infections will adversely affect mortality, disease transmission, and duration of 
illnesses. UPEC is usually obtained by fecal contamination of the urethra and bladder. The two 
most common causes of this are improper wiping and sexual intercourse. When urinary tract 
infections (UTIs) are untreated, UPEC will move superiorly to infect the ureters and the kidneys 
leading to pyelonephritis. In rare instances, the bacteria can leave the kidneys and enter the 
bloodstream leading to bacteremia. For years the mainstay treatment for UTIs has been a 
regimen of antibiotics. In the United States (U.S.), treatment guidelines for an uncomplicated 
UTI call for a 3-day course of trimethoprim-sulfamethoxazole (TMP-SMX).7 
In the U.S., there are an estimated 8 million cases of UTIs per year.3 Women have nearly 
a 50% lifetime risk of suffering from a UTI.  This corresponds to a 10.8% annual risk for women 
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aged 18 years and over to get a UTI.3 In Nicaragua, data suggests this problem appears to be 
even more severe.3 Escherichia coli is the most frequently isolated uropathogen in symptomatic 
UTIs worldwide, and in Nicaragua as well. In 2008 in Leon, Nicaragua, a study investigated the 
microbial cause in patients with symptomatic UTIs, and Escherichia coli was isolated 44.8% of 
the time to make it the most commonly isolated uropathogen in the country3 (Table 1).   
Globally, increasing resistance rates to frequently used antibiotics has hampered the 
clinical management of UTIs. In particular, Nicaragua has alarming resistance patterns of 
frequently observed uropathogens, like Escherichia coli. Bours et al. (2010) assessed antibiotic 
resistance in the Escherichia coli samples that were isolated (Table 2). The study showed high 
resistance rates to TMP–SMX (38.6%), which is commonly used as a first-line antibiotic for 
UTIs around the world. It also showed resistance to other common and inexpensive orally 
administered agents, such as ampicillin (61.4%) and ciprofloxacin (31.8%).3 When using 
inadequate antibiotics, the risk of clinical failure is high, therefore, usage of these agents 
becomes clinically unacceptable.3 The only drugs against Escherichia coli to which the 
susceptibility rate was high enough to be clinically acceptable to treat UTIs (higher than 80%) 
were nitrofurantoin (93.0%) and amikacin (95.3%).3 Due to the high clinical rate and 
significance of Escherichia coli in UTIs, this data highlights the increased need to mitigate 
antibiotic resistance in Nicaragua. 
If preventive and containment measures are not applied locally, nationally and 
internationally, the limited interventions in one country can compromise the effectiveness of 
antibiotics globally. Improper management of antibiotic resistance in Nicaragua and the rest of 
the developing world can endanger the policies of containment used by even the best-managed 
countries of the world. Antibiotic resistance is therefore a global problem, requiring integrated, 
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global solutions, as there are no boundaries to its worldwide spread.4 To help developing 
countries establish a system that can help curb antibiotic resistance, countries can turn to an 
approach recommended by the World Health Organization (WHO) called the ‘One Health’ 
approach. This approach is a cross-sectional, collaborative approach to improve health and well-
being through the prevention of risks and the mitigation of effects of crises that originate at the 
interface between humans, animals, and their various environments. 
The control of infectious diseases is seriously threatened by the steady increase in the 
number of microorganisms that are resistant to antimicrobial agents.2 Antibiotics will be key to 
fighting these infections and preventing morbidity and mortality. This paper aims to highlight the 
problems Nicaragua and other developing countries face that can lead to antibiotic resistance in 
bacteria like Escherichia coli. In addition, this paper will explore what strategies might be used 
to reduce antibiotic resistance and the associated morbidity and mortality of infectious diseases, 
especially related to Escherichia coli infections. 
Background 
Treatment Guidelines 
In modern medicine, treatment guidelines are often used as guidance for healthcare 
providers to select the appropriate medications for a particular infection. As a result, the use of 
guidelines has become a particularly effective way to control antibiotic use in healthcare. 
Practice and treatment guidelines have been shown to have a positive effect on the incidence of 
multidrug-resistant infections in both developed and developing countries.4 Guidelines are based 
on current antibiotic susceptibility to infectious agents in a local community and should be 
adjusted based on this data. 
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Before 2003, no treatment guidelines were used for UTIs in Nicaragua. In 2003, Matute 
et al. showed the need for UTI treatment guidelines in Nicaragua due to the high resistance rates 
in Escherichia coli to commonly used antibiotics such as ampicillin, TMP-SMX, and 
ciprofloxacin (Table 2). In accordance to results of the study, new therapeutic guidelines were 
initiated. Ceftriaxone (0% resistance) was to be used for upper UTIs and nitrofuratoin (0% 
resistance) was to be used for lower UTIs.6 These new guidelines would aim to reduce the use of 
ineffective antibiotics, therefore, decreasing antibiotic resistance in antibiotics not being used. 
These guidelines were followed for 5 years until another study looking at Escherichia 
coli antibiotic resistance in UTIs was performed in 2008.3 Reduced usage of β-lactam antibiotics 
had resulted in a decline in resistance to ampicillin (74% to 61.4%) and ampicillin–clavulanate 
(34% to 18.6%). Resistance to TMP–SMX has also declined (68.3% to 38.6%).3,6 However, the 
opposite effect was seen in the guideline’s first-line antibiotics. Globally, nitrofurantoin is the 
preferred treatment for lower UTIs.7 An increase in resistance to nitrofurantoin was seen for 
Escherichia coli (0% to 7%) in Nicaragua.3,6 Additionally, ceftriaxone was the preferred 
treatment for upper UTIs according to the 2003 guidelines. Ceftriaxone saw a large increase in 
resistance rates from 2003-2008 (0% to 20.5%). The increase made ceftriaxone no longer 
clinically acceptable, since it now had a resistance rate greater than 20%.3,6 These results showed 
an increase in resistance to antibiotics used frequently and a decrease in antibiotics used less 
frequently. This highlights the power humans can possess in controlling antibiotic resistance by 
initiating and changing guidelines according to antibiotic resistance rates.  
Surveillance 
The power of guidelines emphasizes the need for frequent surveillance of the prevalence 
of antibiotic resistance in communities so treatment guidelines can be evaluated and changed 
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accordingly. Bours et al. in 2010 showed the benefit of surveillance. With ceftriaxone being 
clinically unacceptable to treat upper UTIs at 20.5% resistance, new guidelines had to be made to 
mitigate resistance and to give patients appropriate antibiotic treatment that was at a low risk of 
clinical failure. Therefore in 2010, amikacin (2.8% resistance) became the new first-line 
treatment for upper UTI infections.3 Although amikacin may be effective to fight against bacteria 
like Escherichia coli, amikacin may not be the best first-line treatment in countries like 
Nicaragua because it is an intramuscular injection. Amikacin must be given as an injection at a 
doctor’s office where there are added costs for drug administration and clean syringes.  If an 
individual is self-medicating for a UTI, an injectable antibiotic will not be the drug of choice at 
the counter and the individual will not be receiving a first-line treatment.   
Without surveillance, suitable antibiotic choice for guidelines cannot be accessed.  
Setting up guidelines and surveillance protocols in developing countries like Nicaragua could be 
a useful strategy to reduce antibiotic resistance. 
Improper Prescribing 
Guidelines can be very helpful, but are only helpful if followed correctly. Improper 
prescribing in Nicaragua and developing countries is another source contributing to antibiotic 
resistance. den Engelsen et al. investigated antibiotic prescribing in an emergency department of 
a hospital in Leon, Nicaragua in 2005. The most prevalent infections at this emergency 
department were respiratory tract infections, urogenital infections, and GI infections. The study 
looked specifically at UTI treatments in the emergency room (ER). According to the national 
guidelines, nitrofuratoin is the first-line antibiotic choice in uncomplicated UTIs. Only 5.3% of 
patients in the ER received the first-line antibiotic. Approximately a quarter of patients did not 
receive the top three recommended antibiotics (nitrofurantoin, ciprofloxacin, and 
8	
amoxicillin/clavulanic acid) according to the guidelines from 2005.8 According to den Engelsen 
et al., a possible reason for the misuse of antibiotics in the Leon ER is due to physicians and 
healthcare providers having a lack of awareness of the guildelines, lack of familiarity with the 
guidelines, or lack of agreement to the guidelines.8 If healthcare providers fail to follow 
treatment guidelines and effective antibiotics are not used, there is an increased risk of clinical 
failure, which will lead to increased morbidity, mortality and healthcare expenditure. 
Research shows that the use of antibiotics in Nicaragua is not optimal. Antibiotics were 
prescribed too frequently and not according to national guidelines when treating for UTIs, 
exacerbating the growing antibiotic resistance problem in Nicaragua.  
Access to Medications and Healthcare Providers 
 Infectious diseases are the fifth leading cause of death in Nicaragua and continue to be a 
leading cause of death in the developing world.6,7 Therefore, antibiotics are a crucial resource in 
fighting infectious disease. However, antibiotics are not always easy to obtain for Nicaraguans 
and citizens in developing countries. 
 Nicaragua’s health system exists of 32 hospitals, 176 health centers and 849 health 
posts.7 Most of the hospitals are concentrated in the cities, which makes healthcare access 
difficult for individuals in rural areas of the country. Nicaragua has 0.91 physicians per 1,000 
inhabitants. Comparatively, the United States has 2.55 physicians per 1,000 inhabitants. Sweden, 
considered the second best healthcare systems in the world (US news), has 4.11 physicians per 
1,000 inhabitants.11 
 Inaccessibility of healthcare providers and facilities in the developing world is one of 
several factors that may have a role in the development of antibiotic resistance. Professional 
healthcare providers are often not the first point of care. With the lack of practitioners and access 
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to healthcare, patients often obtain their drugs and medical advice from unsanctioned stall 
keepers, itinerant vendors, hawkers, and purveyors of other materials.5 This is a problem because  
drug vendors are licensed to sell antimicrobials such as antibiotics, but lack the knowledge to 
dispense or offer proper drug treatment advice.  
 In developed countries, the desire to self-medicate with antibiotics is present, but 
individuals are limited to do so by prescription-only regulations. Although enforcing national 
regulations is effective in curbing self-medication, it is not easily accomplished in developing 
countries.8 When enforcement is present where antibiotics are usually freely available, there have 
only been rare reports of reduction in antibiotic use.5 The sale of antibiotics is a lucrative 
business as long as the demand for antibiotics is high. The best way to approach this would be 
through consultation, education, and cooperation among all interest groups. Although 
cooperation between all groups is ideal, it requires a level of commitment that is not the norm in 
countries like Nicaragua.5 
 Due to the presence of self-medication and lack of healthcare providers to give proper 
drug treatment advice, patients do not always take their antibiotics properly, which can lead to 
increased antibiotic resistance. In a Mexican study, 60% of patients failed to adhere to their 
antibiotic regimen. One of the predisposing factors was inadequate provider-patient relations, 
which in developing countries often arises because of low physician/patient ratios.5 As stated 
earlier, this low physician/patient ratio is present in Nicaragua, so individuals often seek out 





Antibiotics Use in Agriculture 
 Another source of antibiotic resistant Escherichia coli in Nicaragua and other countries 
seems to come from agriculture. Extensive antibiotic use in agriculture as growth promoters in 
animals and as prophylactics against infectious diseases has lead to an increase in antibiotic 
resistance in the food chain, which is often neglected and under-estimated. 4 Antibiotic resistant 
bacteria present in the food chain infect humans indirectly through consumption of contaminated 
food products or directly through exposure to biological substances such as blood, urine, feces, 
and saliva.4 Since antibiotics are widely used in aquaculture, livestock production, and crops, the 
occurrence of antibiotic resistance in the food chain is considered a cross-sectoral problem.4  
 Several studies having reported food animals and products being colonized and 
contaminated by deadly antibiotic-resistant strains, such as methicillin-resistant Staphylococcus 
aureus (MRSA) and Campylobacter spp.4 When specimens are taken from our food animals and 
products, Escherichia coli is one of the most prevalent antibiotic resistant organisms found in 
livestock in the developing and developed world (Table 3).4 With the world being more 
interconnected with the expansion of the human population and international travel, antibiotic 
resistance can easily spread globally via the food chain. 
 In high-resource developed countries, a variety of systems to monitor antibiotic resistance 
in food animals, food products, and humans have been implemented. In contrast with developed 
countries, the majority of low-income developing countries have no systems to monitor 
antibiotic resistance in food animals, food products, and humans. Therefore, antibiotic resistance 
in developing countries is only partially documented, and is dependent on point-prevalent data 
rather than long-term data. To help limit the spread of antibiotic resistance in the food chain, 
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integrated food chain surveillance systems and well-controlled extensive farming practices must 
be implemented. 
 In developing countries, controlled use of antibiotics in animal farming is not being 
practiced. One policy that could be implemented is the unrestricted access of antibiotics to 
farmers, which should be prohibited unless under veterinary prescription or oversight.  
Waste Water Plants 
 Residues of human and veterinary drugs are primarily introduced into the environment 
via discharges from waste water treatment plants or land application of sewage sludge and 
animal manure.9 With agriculture and medical waste comes a route by which resistance genes 
can be introduced into natural bacterial ecosystems where antibiotic resistance can proliferate.9 
 A study was performed in Leon, Nicaragua looking at various water sources and found 
high levels of antibiotic resistant Escherichia coli in hospital sewage water and in 8 of 87 well-
water samples.9 The most common resistance was to ampicillin, chloramphenicol, ciprofloxacin, 
nalidixic acid, and TMP-SMX. Of the isolates, 19% had multi-resistant profiles to ampicillin, 
ceftazidime, ceftriaxone, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid 
and trimethoprim-sulfamethoxazole.9 
 Research shows that waste water treatment plants provide a reservoir for bacteria and 
favorable conditions for the proliferation of antibiotic resistance and spread of resistance genes 
to non-resistant bacteria. Thus, it highlights the importance of creating risk management 
strategies to monitor waste water environments for the spread of antibiotic-resistant bacteria. 
Methods 
This research was conducted through a review of the literature including a PubMed 
search using the search operators “antibiotic resistance, Escherichia coli, urinary tract infections, 
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Nicaragua, developing countries, and clinical guidelines” were used, and articles were filtered 
based on relevance and date of publication during June and July 2017. Articles over 15 years old 
were not referenced. Government websites were utilized to obtain background information on 
healthcare and poverty. In addition, interviews were conducted with Karla Rias Cisneras, a 
pharmacist in Managua, Nicaragua, on July 11th, 2017 and with Dr. Leonel Arguello, 
epidemiologist and president of the Nicaraguan Association of General Practioners, on July 14th, 
2017. 
Discussion 
 In Nicaragua, approximately 30% of the population lives on less than $2 per day. In rural 
areas, poverty rates are especially high, where 50% of households live in extreme poverty.8 
Poverty is a key reason why developing countries are at a higher risk for increased antibiotic 
resistance. Nicaragua simply lacks the resources to fight antibiotic resistance the way the 
developed world does. In an ideal world, developing countries would have the resources needed 
to implement strategies and programs, such as surveillance protocols, waste water management, 
and healthcare provider education programs. If initiated, these programs could improve the 
healthcare system and prevent the development of antibiotic resistance organisms. 
 Therapeutic guidelines can have a powerful role on the control of antibiotic resistance.  
However, without the resources and personnel to perform antibiotic resistance research in the 
community, proper guidelines cannot be made or updated according to current trends in 
antibiotic resistance. In an interview with Dr. Leonel Arguello, epidemiologist and president of 
the Nicaraguan Association of General Practioners, he confirmed that there is not enough 
research being done in the field of antibiotic resistance in Nicaragua. He also emphasized the 
lack of concern towards antibiotic resistance in the healthcare community. Lack of concern by 
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healthcare providers may lead to prescribing practices that negatively effect antibiotic resistance. 
To combat these problems, consultation, education, and cooperation must be initiated in the 
healthcare community. 
 The presence of self-medication in Nicaragua was confirmed in an interview with Karla 
Rias Cisneras, a pharmacist in Nicaragua. Many sick individuals in Nicaragua will receive their 
medical advice and treatment from local pharmacies where they can buy any antibiotic without a 
prescription. Pharmacists are not as well trained in medical diagnoses in Nicaragua and most 
seem to just be aware of only the most basic antibiotics. For instance, Ms. Cisneras said she 
would recommend azithromycin for any problem related to the throat or neck region.  To make 
matters worse, a lot of these pharmacies do not have pharmacists working, and storeowners with 
no education will be the ones that recommend antibiotic treatments to sick individuals.  With the 
level of poverty in Nicaragua, these storeowners are simply trying to move their antibiotics off 
the shelves for profit.  
 Poverty can also drive people from only purchasing a partial antibiotic regimen, which is 
human behavior that can lead to antibiotic resistance. For instance, if an individual needed a 10-
day course, they may only buy 3 days worth to save money.  With the lack of proper resources 
and infrastructure, developing countries struggle to initiate proper waste water management to 
combat antibiotic resistance.  The government also lacks the resources and awareness to initiate 
enforcement of antibiotics used in agriculture. 
 Since humans, animals, agriculture, and the environment all contribute to antibiotic 
resistance, it can be difficult to contain. If possible, developing countries should use the One 
Health approach endorsed by the World Health Organization (WHO). 'One Health' is an 
approach to designing and implementing programs, policies, legislation and research in which 
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cross-sectional collaborations between groups involved in humans, animals, and their various 
environments, come together to achieve better public health outcomes. An example would be 
programs that would monitor antibiotic resistance in humans, animals, and water environments. 
 Although monitoring antibiotic resistance in humans, animals, and their various 
environments would be helpful in a developing country like Nicaragua; monitoring every source 
is not possible with funds being so scarce. Surveillance programs would be most helpful in the 
hospital and clinical settings where patients with UTIs could receive urine cultures and bacteria 
like, Escherichia coli, could be tested for their susceptibility to various antibiotics used to treat 
UTIs. With antibiotic susceptibility information, individual patients would not only receive 
targeted antibiotic therapy based on the results, but antibiotic resistant strains could be recorded 
and sent to a database where trends in resistance could be evaluated. With frequent monitoring, 
treatment guidelines could be more effectively evaluated and changed according to the current 
antibiotic resistant trends.  
 Another useful strategy would be starting an educational program for physicians and 
healthcare providers to provide information to emphasize the significance of antibiotic resistance 
and the importance of using treatment guidelines appropriately and religiously. Based on 
experiences in Nicaragua and interviews with Dr. Arguello and Ms. Cisneros, antibiotic 
resistance had minimal to no coverage during healthcare training in Nicaragua. Therefore, an 
effective strategy may be to educate healthcare providers on the importance and relevance of 
antibiotic resistance during their initial training. By including antibiotic resistance in the 
curriculum, all healthcare providers would be covered during their initial training, and it would 





 With the increasing threat of antibiotic resistant bacteria and the decreasing production of 
new and effective antibiotics, the world is in an evolutionary arms race against some of the 
smallest organisms on earth. Developing countries are at the frontlines of the war. In order to 
take the lead in the war, more must be done in antibiotic resistance research and antibiotic 
development. Governments must be educated on the threat of antibiotic resistance so they can 
help implement appropriate public health programs, policies and legislation. Although there are a 
myriad of things that could be done to combat antibiotic resistance in developing countries like 
Nicaragua, countries unfortunately lack the resources and infrastructure to do so. Since antibiotic 
resistance is a global issue that crosses national borders, international financial support could 
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Table 1. The most frequently isolated microorganisms from UTIs in Leon, Nicaragua.3          
Table 2. Antibiotic resistance from isolated Escherichia coli from UTIs in Leon, Nicaragua.3 
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Table 3. Prevalence of antibiotic-resistant bacteria isolated from food animals and products in developed and 
developing countries.4 
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